Title: Pretreatment CTP collateral parameters predict good outcomes in successfully recanalized middle cerebral artery distal medium vessel occlusions

Vivek Yedavalli, MD, MS<sup>1</sup>, Omar Hamam, MBBS<sup>1</sup>, Meisam Hoseinyazdi, MD<sup>1</sup>, Elisabeth Breese Marsh, MD<sup>2</sup>, Raf Llinas, MD, Victor Urrutia, MD, Richard Leigh, MD, Fernando Gonzalez, MD, Risheng Xu, MD, PhD, Justin Caplan, MD, Judy Huang, MD, Hanzhang Lu, PhD<sup>1</sup>, Max Wintermark, MD, MS, MBA<sup>4</sup>, Jeremy Heit, MD, PhD<sup>5</sup>, Adrien Guenego, MD, PhD, <sup>6</sup> Greg Albers, MD<sup>6</sup>, Kambiz Nael, MD<sup>8</sup>, Argye Hillis, MD<sup>2</sup>.

<sup>1</sup>Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine

Short Title: CTP collateral parameters predict outcomes in DMVOs

## **Corresponding Author:**

Vivek Yedavalli, MD, MS (First and Corresponding Author)

Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine

<sup>&</sup>lt;sup>2</sup> Department of Neurology, Johns Hopkins School of Medicine

<sup>&</sup>lt;sup>3</sup> Department of Neurosurgery, Johns Hopkins School of Medicine

<sup>&</sup>lt;sup>4</sup> Department of Radiology, University of Texas MD Anderson

<sup>&</sup>lt;sup>5</sup> Department of Radiology, Stanford University School of Medicine

<sup>&</sup>lt;sup>6</sup> Department of Radiology, Université libre de Bruxelles

<sup>&</sup>lt;sup>7</sup> Department of Neurology, Stanford University School of Medicine

<sup>&</sup>lt;sup>8</sup> Department of Radiology, David Geffen UCLA School of Medicine

Phipps B112-D

Baltimore, MD 21287

Vyedava1@jhmi.edu

Key words: Acute Ischemic Stroke, Medium Vessel Occlusion, Perfusion Imaging, CT

Perfusion, Collateral Imaging

**Total Word Count: 3754** 

Abstract:

Background: Distal medium vessel occlusions (DMVOs) account for a large percentage of vessel

occlusions resulting in acute ischemic stroke (AIS) with disabling symptoms. We aim to assess

whether pretreatment CT Perfusion collateral status (CS) parameters can serve as imaging

biomarkers for good clinical outcomes prediction in successfully recanalized middle cerebral

artery (MCA) DMVOs.

Methods: We performed a retrospective analysis of consecutive patients with AIS secondary to

primary MCA-DMVOs who were successfully recanalized by mechanical thrombectomy (MT)

defined as modified thrombolysis in cerebral infarction (mTICI) 2b, 2c, or 3. We evaluated the

association between cerebral blood volume (CBV) index and hypoperfusion intensity ratio (HIR)

independently with good clinical outcomes (modified Rankin score (mRS) 0-2) using Spearman

2

rank correlation, logistic regression, and ROC analyses.

Results: From 8/22/2018 to 10/18/2022, 60 consecutive patients met our inclusion criteria (mean age 71.2 +- 13.9 years old [mean+-SD], 35 female). CBV index (r = -0.693, p < 0.001) and HIR (0.687, p < 0.001) strongly correlated with 90-day mRS. A CBV index >= 0.7 ((OR 2.27 [6.94 - 21.23], p = 0.001)) and absence of prior stroke (0.13 [0.33 - 0.86]), p = 0.024) were independently associated with good outcomes. ROC analysis demonstrated good performance of CBV Index in predicting good 90-day mRS (AUC 0.73, p = 0.003) with a threshold of 0.7 for optimal sensitivity (71% [52.0-85.8%]) and specificity (76% [54.9 - 90.6%]). HIR also demonstrated adequate performance in predicting good 90-day mRS (AUC 0.77, p = 0.001) with a threshold of 0.3 for optimal sensitivity (64.5% [45.4-80.8%]) and specificity (76.0% [54.9 - 90.6%]).

<u>Conclusions</u>: A CBV index  $\geq$  0.7 and HIR < 0.3 are independently associated with good clinical outcomes in our cohort of AIS caused by MCA-DMVOs that were successfully treated with MT.

Non-standard Abbreviations and Acronyms: Distal medium vessel occlusions = DMVOs, acute ischemic stroke = AIS, CT Perfusion = CTP, CT angiography = CTA, non-contrast CT = NCCT, collateral status = CS, middle cerebral artery = MCA, mechanical thrombectomy = MT, modified thrombolysis in cerebral infarction = mTICI, cerebral blood volume = CBV, hypoperfusion intensity ratio = HIR, modified rankin score = mRS, anterior cerebral artery = ACA, large vessel occlusion = LVO, time-to-maximum = Tmax, NIH stroke scale (NIHSS), hemorrhagic transformation = HT, intravenous tissue plasminogen activator = IV tPA, Alberta Stroke Program Early CT Score = ASPECTS, kilovoltage peak = kVp, milliampere-seconds = mAs, body mass index = BMI, systolic blood pressure = SBP, diastolic blood pressure = DBP, heart rate = HR, respiratory rate = RR.

# **Introduction:**

Distal medium vessel occlusions (DMVOs) - defined as M2-M4 segments of the middle cerebral artery (MCA), anterior cerebral artery (ACA) segments and vertebrobasilar branches - are thought to represent 25-40% of acute ischemic stroke (AIS) and can result in disabling symptoms <sup>1</sup>. The current standard of care treatment for AIS caused by DMVOs is IV thrombolysis but fails to successfully recanalize DMVOs in up to two thirds of patients <sup>1</sup>. With the recent technological advances, DMVOs are now increasingly being treated with mechanical thrombectomy (MT) despite current lack of consensus on guidelines <sup>2</sup>.

Robust collaterals have been shown to predict good outcomes in large vessel occlusions (LVOs), but the effect of collateral status (CS) on DMVOs is still an area of ongoing research. Although CT angiography-based CS grading can be performed, there is significant variability amongst readers, necessitating automated quantitative pretreatment CT perfusion (CTP) CS assessments  $^{3,4}$ . The cerebral blood volume (CBV) Index – defined as the mean rCBV obtained by dividing the average of all CBV values from the time-to-maximum (Tmax) > 6 s region within the ischemic hemisphere by the average of all CBV values from all tissue with Tmax  $\leq 4$  s  $^5$  - and the hypoperfusion intensity ratio (HIR) - defined as time to maximum (Tmax) greater than 10 seconds volume divided by the Tmax greater than 6 second volume  $^{6-8}$  - have both been previously validated as reliable quantitative CS parameters, particularly for middle cerebral artery (MCA) LVOs. Prior LVO studies have reported thresholds of greater than 0.8 for CBV index  $^9$  and approximately 0.4 for HIR  $^8$ , where patients with greater than 0.8 or HIR less than 0.4 have good CS. However, despite being established in LVOs, no studies to our knowledge have

assessed the optimal CBV Index threshold for MCA-DMVOs. Furthermore, the optimal threshold for HIR in MCA-DMVOs still remains underexplored.

Therefore, the primary aim of our study was to establish a threshold for CBV Index in patients with AIS due to primary MCA-DMVOs who were successfully recanalized by MT for clinical outcomes prediction. We hypothesize that the LVO threshold of approximately 0.8 for CBV index still applies to DMVOs. Our secondary aim is to also determine the predictive value of HIR in the same setting with comparison to CBV Index in order to assess the value of each CS parameter in the same cohort. For this aim, we hypothesize that a more restrictive threshold compared to the LVO threshold of 0.4 is optimal due to the longer transit time to the affected tissue. Specifically, we postulate that the previously suggested threshold of 0.3<sup>10</sup> is optimal.

# **Methods:**

## Population and Study Design:

In this retrospective study, we identified consecutive patients from two comprehensive stroke centers within the Johns Hopkins Medical Enterprise (Johns Hopkins Hospital - East Baltimore and Bayview Medical Campus) from 8/22/2018 to 10/18/2022 in a continuously maintained database. This study was approved through the Johns Hopkins School of Medicine institutional review board (JHU-IRB00269637) and follows the STROBE checklist guidelines as an observational study<sup>11</sup>.

5

The inclusion criteria for this study were as follows: a) MT triage within 24 hours of symptom onset or last known well; b) diagnostically adequate multimodal pretreatment CT imaging including NCCT, CTA, and CTP; c) AIS due to a CT angiography (CTA) confirmed MCA-DMVO, specifically including M2-M4 segments of the MCA as defined by Saver et al<sup>1</sup>; and d) successful recanalization by MT defined as modified thrombolysis in cerebral infarction (mTICI) 2b or 3.

The study was conducted in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act (HIPAA). Informed consent was waived by the institutional review boards given the retrospective study design.

The decisions to administer intravenous tissue plasminogen activator (IV tPA) and/or perform MT were made on an individual basis based on consensus stroke team evaluation per our institution protocols and were controlled for in our analyses.

## Data Collection:

Baseline and clinical data were collected through electronic records and stroke center databases for each patient included demographics, risk factors for AIS (including diabetes mellitus, hypertension, coronary artery disease, atrial fibrillation), admission glucose, admission NIH stroke scale (admission NIHSS), Alberta Stroke Program Early CT Score (ASPECTS), site of occlusion, and laterality of occlusion, and IV thrombolysis administration. Additional collected parameters included number of passes, recanalization time, mTICI score; presence of complication such as hemorrhagic transformation (HT) as defined by the ECASS trial. Patients

6

were subsequently grouped into good and poor CS based on the statistically determined optimal CBV threshold (please see below).

## **Imaging Analysis:**

The ASPECTS scores were calculated on non-contrast CT (NCCT) and baseline CTAs were reviewed for presence and site of DMVO by an experienced neuroradiologist (VSY, 6 years of experience). The same neuroradiologist assessed the diagnostic adequacy of the CTPs where only those deemed diagnostic adequate were included in the study.

#### Imaging parameters:

NCCT: NCCT is performed in a helical mode at 5 mm slice thickness with 0.75 mm; reconstructions (120 kilovoltage peak (kVp), 365 milliampere-seconds (mAs), Rotation Time 1 second, Acquisition Time 6 - 8 seconds, Collimation 128 x 0.6 mm, Pitch Value 0.55, Scan Direction Craniocaudal).

CTA: The CTA of the head and neck is performed with non-ionic iodinated contrast with 50-70 ml injected at 5-6 ml/second from the aortic arch through the vertex using a bolus triggered method at 3 mm slice thickness with 0.75 mm reconstructions. The CTA parameters are as follows: 90/150 kVp with an Sn filter, Quality Reference mAs 180, Rotation Time 0.25 seconds, Average Acquisition Time 3-5 seconds, Collimation 128 x 0.6 mm, Pitch Value 0.7, Scan Direction Craniocaudal.

CTP: CTP is then performed with injection of 50 ml non-ionic iodinated contrast with a 30 ml saline flush at 5-6 ml/second with anatomic coverage of 70-100 mm at 5 mm slice thickness. Parameters as follows: 70 kVP, 200 Effective mAs, Rotation Time 0.25 seconds, Average Acquisition Time 60 seconds, Collimation 48 x 1.2 mm, Pitch Value 0.7, 4D Range 114 mm x 1.5 seconds, Scan Direction Craniocaudal. CTP images are then post-processed using RAPID commercial software (IschemaView, Menlo Park) for generating Tmax maps, from which the HIR and CBV Index are calculated.

### Angiographic Assessment:

The pre-MT DSA collateral assessment was performed by two experienced neuroradiologists (MH and VSY, 3 and 6 years of experience respectively) using the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) criteria<sup>12</sup>. Any discrepancies were assessed with a final score based on consensus evaluation. Grades 3 and 4 were categorized as good CS. Although Grade 2 is considered moderate CS, it was included in the poor CS group for dichotomized analysis.

The mTICI score was determined by the performing neurointerventionalist at the time of the procedure.

#### Clinical Outcomes Assessment:

Modified Rankin scores at discharge and 90 days (90 day mRS) in addition to discharge NIHSS were determined by a stroke neurologist or certified nurse practitioner.

8

Outcome Measures:

The primary outcomes were good clinical outcomes defined as 90-day mRS 0-2. The secondary outcomes included excellent outcomes (90-day mRS 0-1), discharge mRS, discharge NIHSS, and

NIHSS shift (defined as the difference between discharge and admission NIHSS).

Statistical analysis:

The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics

(Statistical Package for Social Sciences) software version 28.0, IBM Corp., Chicago, USA, 2021.

Quantitative data were tested for normality using Shapiro-Wilk test, then if normally distributed

described as mean±SD (standard deviation) as well as minimum and maximum of the range. If

data were not normally distributed, they were described as Median (1st-3rd Interquartiles) as

well as minimum and maximum then compared using Mann Whitney test. Correlations between

HIR and CBV Index as well as CBV Index with DSA CS and 90-day mRS were assessed by

Spearman rank correlation. Receiver operating characteristics (ROC) curve was used to evaluate

the performance of HIR and CBV Index where the optimal thresholds to predict 90-day mRS of

0-2 based on highest sensitivity and specificity were determined. Multivariate logistic regression

analyses were also performed to assess the association of CBV index with 90-day mRS. Patients

were then grouped based on the determined CBV optimal threshold. The level of significance

taken at P value  $\leq 0.050$  was significant, otherwise was non-significant.

**Results:** 

From 8/22/2018 to 10/18/2022, we identified 147 consecutive patients with AIS due to an MCA-

9

DMVO. Of these 147 patients, 60 patients (mean age 71.2 +- 13.9 years old [mean+-SD], 35

female) met the inclusion criteria and were included in this study. In total, 56 out of the 60 patients had available 90-day mRS. All patients had discharge mRS and discharge NIHSS available. Please see Table 1 for demographic information.

Of the 60 patients, 51 had M2 occlusions (51/60, 85%), 6 had M3s (6/60, 10%), and 3 had M4s (3/60, 5%). See Table 1.

Nineteen patients received IV thrombolysis (19/60, 31.7%) prior to MT. Forty-six (46/60, 76.7%) had pretreatment DSA that was adequate for CS assessment. Forty-three patients achieved mTICI 3 recanalization (43/60, 71.7%). Hemorrhagic transformation of any subtype was found in 15 patients (15/60, 25%). A higher percentage of moderate and good CS based on DSA were found in the CBV >= 0.7 group (4/6 vs 2/6, grade 2 and 14/20 vs 6/20, grade 3; p = 0.004) compared to the CBV < 0.7 group. Moreover, a higher percentage of poor CS based on DSA was found in the CBV < 0.7 group (4/4 vs 0.4 grade 0; 6/6 vs 0/6 grade 1; p = 0.004) versus the CBV >= 0.7 group. Based on dichotomized DSA CS assessment, a higher percentage of good CS patients (19/30 vs 11/30) and a lower percentage of poor CS patients (4/16 vs 12/16) were also seen in the CBV >= 0.7 group (p = 0.013). HIR was also lower in the CBV >= 0.7 group (0.3 [median, IQR] [0.0-5.0] vs 0.5 [0.3-0.6; p = 0.001]. See Table 2.

Outcomes analysis revealed significantly lower 90 day mRS ( [median, IQR] 1.0 [0.0-2.0] vs 4.5 [3.0 - 6.0], p < 0.001), discharge mRS (2.0 [2.0-3.0] vs 4.0 [3.0 - 5.0], p < 0.001), and discharge NIHSS (2.0 [1.0-5.0] vs 6.0 [2.0 - 12.0], p = 0.001) in the CBV  $\geq$  0.7 group. A larger favorable

NIHSS shift was also found in the CBV  $\geq$ = 0.7 group (-10.5 [-16.0- -4.0] vs -3.0 [-6.0 - 3.0], p < 0.001). Please see Table 2 for details.

### Correlation analysis:

CBV Index demonstrated a strong inverse correlation with 90-day mRS (-0.693, p < 0.001) and moderate inverse correlation with HIR (-0.494, p < 0.001). HIR also demonstrated a strong positive correlation with 90-day mRS (0.687, p < 0.001). CBV Index nor HIR were significantly correlated with DSA CS assessment. Please see Table 3.

## **ROC** analysis:

ROC analysis demonstrated adequate performance of CBV Index in predicting good 90-day mRS (AUC 0.73, p = 0.003) with a threshold of 0.7 for optimal sensitivity (71% [52.0-85.8%]) and specificity (76% [54.9 - 90.6%]). CBV index also predicted excellent 90 day mRS (AUC 0.73, p = 0.003).

HIR also demonstrated good performance in predicting good 90-day mRS (AUC 0.77, p = 0.001) with a threshold of 0.3 for optimal sensitivity (64.5% [45.4-80.8%]) and specificity (76.0% [54.9 - 90.6%]). HIR also predicted excellent 90-day mRS (AUC 0.741, p = 0.002). Please see Figure 1.

No significant differences were noted between the diagnostic performances of the CBV index and HIR thresholds with respect to predicting good 90-day mRS (p = 0.558). Please see Table 4.

# Multivariate regression analysis:

A CBV index of >=0.7 (OR 2.27 [6.94 - 21.23], p = 0.001) was significantly associated with good outcomes. Furthermore, prior stroke (0.13 [0.33 - 0.86]), p = 0.024) was inversely associated with good outcomes.

## **Discussion:**

In this study, we identify CBV index and HIR thresholds that predict good outcomes after thrombectomy treatment of MCA-DMVOs. We also demonstrate that a CBV index >= 0.7 is an independent predictor of good outcomes in this group of patients. This is the first study to our knowledge to determine a CBV index threshold for successfully recanalized AIS patients with DMVOs.

Although the current standard of care for DMVOs is IV thrombolysis, actual practice is increasingly using MT since IV thrombolysis fails to achieve recanalization in up to half of patients<sup>13</sup>. The advancements in endovascular technology have allowed for better navigation of these smaller caliber and often tortuous vessels. Several studies have demonstrated feasibility and safety of attempting MT in DMVOs<sup>1,2,13,14</sup>, leading to an increased number of these patients being treated with MT.

In light of these advances in intervention, the effect of CS in DMVOs has become more relevant yet requires further investigation. As an established biomarker of infarct growth and outcomes in LVOs<sup>7</sup>, it stands to reason that CS similarly influences outcomes in DMVOs as well. Pretreatment CTP quantitative assessments with CBV index<sup>5,9,15</sup> and HIR<sup>6–8</sup> have been established as imaging biomarkers of CS in LVOs. However, due to the smaller volume of

affected tissue and the longer transit to reach these regions, the same LVO thresholds may not apply to DMVOs, which is the main purpose of our investigation.

As an indicator of the relative blood volume within critically hypoperfused tissue, CBV index is thought to represent an indirect compensatory response to the acute occlusion through collateralization. Our results indicate that a threshold of 0.7 where a pretreatment CBV index of 0.7 or greater predicts good clinical outcomes. This threshold is lower than the established LVO threshold of greater than 0.8 for 24-hour infarct volume prediction<sup>9</sup>. In direct comparison with respect to DMVOs, the 0.7 threshold is more accurate (73.2% versus 60.7%) and more sensitive (71.0% versus 35.5%) than 0.8, although less specific (76% versus 92%) in predicting good clinical outcomes. We postulate that the lower CBV index for MCA-DMVOs determined in our study is due to the smaller area of affected tissue where, where compared to LVOs, a less robust compensatory response may suffice to maintain tissue viability.

Interestingly, we did not find a correlation between DSA and both CBV index and HIR, respectively. However, we found a strong inverse correlation between CBV index and 90-day mRS in addition to a strong direct correlation between HIR and 90-day mRS. This discordance between both CS parameters' correlations with 90-day mRS and DSA may be due to a smaller sample of patients with DSA CS assessments. In our cohort, 46 patients (46/60, 76.7%) had DSAs that were imaged long enough to perform adequate CS assessments. Furthermore, despite DSA being considered the reference standard for CS assessment, prior studies are mixed on the robustness of DSA CS in predicting functional outcomes <sup>3,16,17</sup>. It is possible that both CS parameters capture a compensatory component of CS that may translate completely to DSA but is reflected with subsequent clinical outcomes.

We also assessed the value of HIR as a predictive outcomes measure in successfully recanalized DMVOs. HIR is a well-established CS imaging biomarker in LVOs where a 0.4 threshold has been optimal<sup>6–8</sup>. LVOs patients with an HIR of less than 0.4, thought to represent good CS, has been correlated with good DSA collaterals in M1 occlusions<sup>6</sup>, validated for transferring patients for MT<sup>8</sup>, and predictive of infarct growth rate and clinical outcomes<sup>7</sup> as well as post MT HT<sup>18</sup>. However, the role HIR plays in DMVOs is still being investigated.

Guenego et al most recently concluded that an HIR of less than 0.3 was associated with good CS and predicted less infarct growth in successfully recanalized DMVO cohort of 40 patients <sup>10</sup>. They also found that patients with an HIR equal to or greater than 0.3 had unfavorable outcomes on univariate analysis. However, this did not persist on multivariate analysis 10. Our results are concordant with Guenego et al where we further validate the threshold of 0.3. In our cohort, patients with an HIR less than 0.3 predicted good and excellent outcomes, even doing so slightly superior to CBV index, although the difference was not significant (p = 0.558). Our study also has some notable differences compared to Guenego et al. First, our study has a larger sample size of 60 patients. Our analysis also focused on directly predicting clinical outcomes as opposed to infarct growth as a clinical outcome surrogate. In comparison to the LVO threshold of 0.4, the 0.3 threshold was slightly more accurate (69.6% versus 67.9%) and more specific (76.0% versus 68.0%), although less sensitive (64.5% versus 67.7%) in predicting good clinical outcomes. We hypothesize that this lower threshold for HIR compared to the LVO threshold of 0.4 is likely due to longer transit time to reach the affected region, necessitating a more restrictive threshold.

In addition to our CS parameter assessment, we also report that a history of prior stroke decreases the likelihood of good outcomes in these patients. Prior stroke as a predictive

biomarker is underexplored within this patient population. In a study assessing medium vessel occlusions with discrepant infarct patterns, Ospel et al found a history of prior stroke in 16.4% (43/262) of patients in their cohort<sup>19</sup>. Our cohort had a substantially higher percentage of patients with prior stroke (58.3%, 35/60). The difference in sample size may be the reason for this discrepancy with Ospel et al. Nevertheless, prior stroke is a well-established risk factor for stroke recurrence of all types <sup>20–22</sup> and, for that reason, it is understandable that a similar trend may also apply to the MCA-DMVO population. This may be an area of future research with larger studies.

Our study has several limitations. Firstly, it is inherently limited by its retrospective design. Secondly, we focused on only MCA-DMVOs with a predominance of M2 occlusions, which may introduce a bias. The M2 occlusion predominance is most likely due to the relative proximity of the vessel, making these occlusions more amenable to MT. Thirdly, our analysis is restricted to use of one commercial software platform, which may limit generalizability.

Nevertheless, our study is strengthened by an adequate sample size of 60, given the stringent inclusion criteria of successfully recanalized MCA-DMVOs with MT. Our cohort consists of two comprehensive stroke centers serving different demographics, therefore improving generalizability.

In conclusion, the use of automated pretreatment CTP CS measures may have promise in everyday clinical practice. Currently, to our knowledge, no threshold for CBV index in the setting of DMVOs exists. Moreover, the utility of HIR in DMVOs still requires additional exploration. Our study demonstrates that, in comparison to LVO thresholds, a lower CBV index and a more restrictive HIR are associated with improved clinical outcomes in successfully recanalized MCA-DMVO patients. Given the prevalence of DMVOs, these thresholds have potential utility in everyday clinical practice as additional predictive imaging biomarkers in this

group. Nevertheless, larger scale studies must be performed to further assess the strength of our results.

**Acknowledgements: None** 

**Sources of Funding: None** 

**Disclosures:** Drs. Jeremy Heit and Vivek Yedavalli disclose roles as consultants for RAPID (iSchemaView, Menlo Park, CA). Dr. Greg Albers is the co-founder of RAPID.

# **References:**

- 1. Saver JL, Chapot R, Agid R, Hassan AE, Jadhav AP, Liebeskind DS, Lobotesis K, Meila D, Meyer L, Raphaeli G, et al. Thrombectomy for Distal, Medium Vessel Occlusions: A Consensus Statement on Present Knowledge and Promising Directions. *Stroke*. 2020; 51:2872–2884.
- 2. Guenego A, Mine B, Bonnet T, Elens S, Vazquez Suarez J, Jodaitis L, Ligot N, Naeije G, Lubicz B. Thrombectomy for distal medium vessel occlusion with a new generation of Stentretriever (Tigertriever 13). *Interventional Neuroradiology*. 2022;28(4):444-454.
- 3. Kauw F, Dankbaar JW, Martin BW, Ding VY, Boothroyd DB, van Ommen F, de Jong HW, Kappelle LJ, Velthuis BK, Heit JJ, Wintermark M. Collateral status in ischemic stroke: a comparison of computed tomography angiography, computed tomography perfusion, and

- digital subtraction angiography. Journal of computer assisted tomography. 2020;44(6):984.
- 4. Wolff L, Su J, Van Loon D, van Es A, van Doormaal PJ, Majoie C, van Zwam W, Dippel D, van der Lugt A, van Walsum T, MR CLEAN investigators. Inter-rater reliability for assessing intracranial collaterals in patients with acute ischemic stroke: comparing 29 raters and an artificial intelligence-based software. *Neuroradiology*. 2022;64(12):2277-2284.
- 5. Arenillas JF, Cortijo E, García-Bermejo P, Levy EI, Jahan R, Liebeskind D, Goyal M, Saver JL, Albers GW. Relative cerebral blood volume is associated with collateral status and infarct growth in stroke patients in SWIFT PRIME. *Journal of Cerebral Blood Flow & Metabolism.* 2018;38(10):1839-1847.
- 6. Guenego A, Fahed R, Albers GW, Kuraitis G, Sussman ES, Martin BW, Marcellus DG, Olivot JM, Marks MP, Lansberg MG, Wintermark M. Hypoperfusion intensity ratio correlates with angiographic collaterals in acute ischaemic stroke with M1 occlusion.
  European Journal of Neurology. 2020;27(5):864-870.
- Olivot JM, Mlynash M, Inoue M, Marks MP, Wheeler HM, Kemp S, Straka M, Zaharchuk G, Bammer R, Lansberg MG, Albers GW. Hypoperfusion intensity ratio predicts infarct progression and functional outcome in the DEFUSE 2 Cohort. *Stroke*. 2014;45(4):1018-1023.
- 8. Guenego A, Marcellus DG, Martin BW, Christensen S, Albers GW, Lansberg MG, Marks MP, Wintermark M, Heit JJ. Hypoperfusion intensity ratio is correlated with patient eligibility for thrombectomy. *Stroke*. 2019;50(4):917-922.
- 9. Rao VL, Mlynash M, Christensen S, Yennu A, Kemp S, Zaharchuk G, Heit JJ, Marks MP, Lansberg MG, Albers GW. Collateral status contributes to differences between observed and predicted 24-h infarct volumes in DEFUSE 3. *Journal of Cerebral Blood Flow &*

- Metabolism. 2020;40(10):1966-1974.
- 10. Guenego A, Farouki Y, Mine B, Bonnet T, Hulscher F, Wang M, Elens S, Vazquez Suarez J, Jodaitis L, Ligot N, Naeije G. Hypoperfusion intensity ratio predicts infarct growth after successful thrombectomy for distal medium vessel occlusion. *Clinical Neuroradiology*. 2022;32(3):849-856.
- 11. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. *European journal of clinical investigation*. 2010;40(1):35-53.
- 12. Liu L, Ding J, Leng X, Pu Y, Huang LA, Xu A, Wong KS, Wang X, Wang Y. Guidelines for evaluation and management of cerebral collateral circulation in ischaemic stroke 2017.

  Stroke and vascular neurology. 2018;3(3).
- 13. Saber H, Desai SM, Haussen D, Al-Bayati A, Majidi S, Mocco J, Hassan AE, Rajah G, Waqas M, Davies JM, Dornbos D. Endovascular therapy vs medical management for patients with acute stroke with medium vessel occlusion in the anterior circulation. *JAMA network open.* 2022;5(10): e2238154-e2238154.
- 14. Farouki Y, Bonnet T, Mine B, Hulscher F, Wang M, Elens S, Suarez JV, Jodaitis L, Ligot N, Naeije G, Walker G. First-pass effect predicts clinical outcome and infarct growth after thrombectomy for distal medium vessel occlusions. *Neurosurgery*. 2022;91(6):913-919.
- 15. MacLellan A, Mlynash M, Kemp S, Ortega-Gutierrez S, Heit JJ, Marks MP, Lansberg MG, Albers GW, DEFUSE 3 Investigators. Perfusion imaging collateral scores predict infarct growth in non-reperfused DEFUSE 3 patients. *Journal of Stroke and Cerebrovascular Diseases*. 2022;31(1):106208.
- 16. Lu WZ, Lin HA, Hou SK, Bai CH, Lin SF. Diagnostic test accuracy of pretreatment collateral score in predicting stroke outcomes after intra-arterial endovascular

- thrombectomy: a meta-analysis in DSA and CTA. *European Radiology*. 2022;32(9):6097-6107.
- 17. Van Den Wijngaard IR, Boiten J, Holswilder G, Algra A, Dippel DW, Velthuis BK,

  Wermer MJ, van Walderveen MA. Impact of collateral status evaluated by dynamic

  computed tomographic angiography on clinical outcome in patients with ischemic stroke.

  Stroke. 2015;46(12):3398-3404.
- 18. Winkelmeier L, Heit JJ, Adusumilli G, Geest V, Christensen S, Kniep H, Van Horn N,
  Steffen P, Bechstein M, Sporns P, Lansberg MG. Hypoperfusion intensity ratio is correlated
  with the risk of parenchymal hematoma after endovascular stroke treatment. Stroke. 2023
  Jan;54(1):135-143.
- 19. Ospel JM, Cimflova P, Marko M, Mayank A, Hafeez M, Almekhlafi MA, Hill MD, Demchuk AM, Menon BK, Goyal M. Prevalence and outcomes of medium vessel occlusions with discrepant infarct patterns. *Stroke*. 2020;51(9):2817-2824.
- 20. Flach C, Muruet W, Wolfe CD, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: a population-base cohort study. *Stroke*. 2020;51(8):2435-2444.
- 21. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. *Stroke*. 1994;25(2):333-337.
- 22. Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke–a systematic review and meta-analysis. *Journal of Stroke and Cerebrovascular Diseases*. 2021;30(8):105935.

# **Tables**

Table (1): Demographic, admission findings, and vessel breakdown according to optimal CBV index threshold

		All cases	CBV Inde		
Variables		(Total=60)	Good CS ≥0.7	Poor CS < 0.7	p-value
		(10tal-00)	(Total=30)	(Total=30)	
Age (years)		71.2±13.9	73.3±15.2	69.0±12.4	^0.230
C	Female	35 (58.3%)	20 (66.7%)	15 (50.0%)	#0 100
Sex	Male	25 (41.7%)	10 (33.3%)	15 (50.0%)	#0.190
D	Black	34 (56.7%)	16 (53.3%)	18 (60.0%)	
Race	White	24 (40.0%)	13 (43.3%)	11 (36.7%)	§0.893
	Asian	2 (3.3%)	1 (3.3%)	1 (3.3%)	
BMI (kg/n	 m <sup>2</sup> )	28.2±5.6	28.3±5.8	28.1±5.6	^0.932
Smoking		31 (51.7%)	15 (50.0%)	16 (53.3%)	#0.796
Alcohol		18 (30.0%)	7 (23.3%)	11 (36.7%)	#0.260
Hypertens	sion	51 (85.0%)	25 (83.3%)	26 (86.7%)	§0.999
Dyslipider	nia	38 (63.3%)	19 (63.3%)	19 (63.3%)	#0.999
Heart dise	ease	20 (33.3%)	10 (33.3%)	10 (33.3%)	#0.999
Prior strol	ke / TIA	35 (58.3%)	16 (53.3%)	19 (63.3%)	#0.432
A-Fib		15 (25.0%)	8 (26.7%)	7 (23.3%)	#0.766
Glucose (r	ng/dL)	143.2±72.7	155.2±93.6	131.2±41.0	^0.204
BUN (mg/	dL)	20.7±11.2	23.3±11.7	18.1±10.3	^0.071
Creatinine	e (mg/dL)	1.2±0.9	1.4±1.2	1.1±0.4	^0.287
Hemoglob	oin (gm/dL)	12.6±1.9	12.4±2.0	12.9±1.7	^0.219
WBC (x10	$0^3/mL$ )	9.7±8.8	10.9±12.1	8.4±2.8	^0.258

Platelets (x10 <sup>3</sup>	Platelets (x10 <sup>3</sup> /mL)		254.8±82.4	230.4±87.7	^0.271
Admission NII	Admission NIHSS		9.0 (4.0–15.0)	13.5 (5.0–19.0)	¤0.208
ASPECTS		9.0 (8.0–10.0)	9.0 (8.0–10.0)	9.0 (8.0–10.0)	¤0.845
	Large artery atherosclerosis	10 (16.9%)	7 (23.3%)	3 (10.3%)	
TOAST	Cardioembolis m	26 (44.1%)	15 (50.0%)	11 (37.9%)	#0.115
	Stroke of undetermined etiology	23 (39.0%)	8 (26.7%)	15 (51.7%)	
Segment	M2 M3 M4	51 (85.0%) 6 (10.0%) 3 (5.0%)	28 (93.3%) 2 (6.7%) 0 (0.0%)	23 (76.7%) 4 (13.3%) 3 (10.0%)	§0.115
Laterality	Left Laterality Right		18 (60.0%) 12 (40.0%)	14 (46.7%) 16 (53.3%)	#0.301
<u>Proximity</u>	Proximal Mid Distal	31 (51.7%) 9 (15.0%) 19 (31.7%)	16 (53.3%) 5 (16.7%) 8 (26.7%)	15 (50.0%) 4 (13.3%) 11 (36.7%)	§0.770

BMI: Body mass index. Data presented as n (%), Mean±SD and Median (1st-3rd IQ). SBP: Systolic blood pressure. DBP: Diastolic blood pressure. HR: Heart rate. RR: Respiratory rate. \*Significant (<0.050), §Fishers Exact test. #Chi square test. ^Independent t-test. ¤Mann-Whitney test.

Table (2): Collateral parameters, interventional parameters, and clinical outcomes based on optimal CBV index threshold

	All cases	CBV Index	based CS		
Variables and Outcomes		Good CS ≥0.7	Poor CS <0.7	p-value	
	(Total=60)	(Total=30)	(Total=30)		
IV tpa	19 (31.7%)	11 (36.7%)	8 (26.7%)	#0.405	
Anesthesia	4 (6.7%)	2 (6.7%)	2 (6.7%)	§0.999	
Number of Passes	1.0 (1.0–2.0)	1.0 (1.0–1.0)	1.0 (1.0–2.0)	¤0.068	
I and large and the Decor (color)	243.0 (63.0–	239.5 (75.0–	244.5 (61.0–	~0.00 <b>2</b>	
Last known well to Door (min.)	594.0)	596.0)	568.0)	□0.882	
S ( )	60.0 (48.0–	60.0 (47.0–	55.0 (48.0–	~0.270	
Symptom onset to Door (min.)	144.0)	146.0)	65.0)	¤0.378	
	26.5 (15.5–	260(150, 250)	27.0 (16.0–	0.750	
Door to CT (min.)	37.0)	26.0 (15.0–37.0)	42.0)	¤0.750	
T. O. C. C. C.	272.0 (86.5–	269.5 (85.0–	281.5 (88.0–	0.002	
Last known well to CT (minutes)	610.0)	619.0)	580.0)	¤0.882	
	67.0 (55.0–	(= 0 (== 0 0= 0)	72.0 (55.0–	0.600	
Door to needle time (min.)	115.0)	67.0 (55.0–87.0)	125.5)	¤0.680	
	148.5 (122.5–	143.5 (111.0–	152.5 (133.0–	0.4.60	
Door to groin puncture (min.)	181.5)	175.0)	195.0)	¤0.169	
Groin Puncture to First Pass	25.0 (18.0–	24.0 (15.0.20.0)	26.0 (20.0–	0 221	
(minutes)	32.0)	24.0 (15.0–29.0)	33.0)	¤0.231	
	418.5 (243.0–	397.0 (258.0–	479.0 (210.0–		
Door to recanalization, (min.)	732.0)	764.0)	715.0)	¤0.824	
First Pass to recanalization,	50/25115	50(2550)	0.0 (4.0.21.0)	0.0=0	
(min.)	5.0 (3.5–11.5)	5.0 (3.5–6.0)	8.0 (4.0–21.0)	¤0.078	

Groin Puncture to re	canalization	32.5 (25.0–	30.0 (20.0–39.0)	40.0 (26.0–	¤0.056
(minutes)		48.0)	30.0 (20.0–39.0)	55.0)	20.036
Hemorrhagic Transf	ormation	15 (25.0%)	5 (16.7%)	10 (33.3%)	#0.136
mTICI score	2b	17 (26.6%)	9 (26.7%)	8 (26.7%)	
m11C1 score	3	43 (71.7%)	22 (73.3%)	21 (70.0%)	0.999
	0	4 (8.7%)	0 (0.0%)	4 (100%)	
	1	6 (13.0%)	0 (0.0%)	6 (100%)	
DSA grades	2	6 (13.0%)	4 (66.7%)	2 (33.3%)	§ <b>0.004</b> *
	3	20 (43.5%)	14 (70.0%)	6 (30.0%)	
	4	10 (21.7%)	5 (50.0%)	5 (50.0%)	
DCA hand CC	Good	30 (65.2%)	19 (63.3%)	11 (36.7%)	µ0 012 <b>÷</b>
DSA based CS	Poor	16 (34.8%)	4 (25.0%)	12 (75.0%)	#0.013*
HIR	I	0.4 (0.1–0.5)	0.3 (0.0–0.5)	0.5 (0.3–0.6)	¤0.001*
NIHSS discharge		2.0 (1.0-6.0)	2.0 (1.0–5.0)	6.0 (2.0–12.0)	¤0.001*
NIHSS shift		-6.0 (-13.0–0.0)	-10.5 (-16.0	20(60.20)	¤<0.001*
NIHSS SHIIL		-0.0 (-13.0-0.0)	4.0)	-3.0 (-6.0–3.0)	u<0.001 °
Discharge mRS		3.0 (2.0–4.0)	2.0 (2.0–3.0)	4.0 (3.0–5.0)	¤<0.001*
90-da7 mRS		2.0 (1.0-4.0)	1.0 (0.0–2.0)	4.5 (3.0–6.0)	¤<0.001*
		1			I

Data presented as n (%), Mean±SD and Median (1st-3rd IQ) \*Significant (<0.050)

§Fishers Exact test. #Chi square test. ^Independent t-test. ¤Mann-Whitney test.

Table (3): Multivariate logistic regression for predicting good clinical outcomes

Factors	β	SE	p-value	OR (95% CI)
		Good 90mRS		
Stroke	-1.10	0.49	0.024*	0.13 (0.33–0.86)
CBV index ≥0.7	1.94	0.57	0.001*	2.27 (6.94–21.23)

β: Regression coefficient, SE: Standard error, OR: Odds ratio, CI: Confidence interval,

<sup>\*</sup>Significant (<0.050)

Table (4): CBV index and HIR correlations with other parameters

Factors	CBV in	ndex	HIR		
2	r	p-value	r	p-value	
90mRS	-0.693	<0.001*	0.687	<0.001*	
DSA	0.236	0.114	-0.134	0.373	
HIR	-0.494	<0.001*			

Spearman correlation. \*Significant (<0.050)

Table (5): Diagnostic performance of CBV index and HIR in predicting good and excellent clinical outcomes

	AUC	p-	Cut	Sensitiv	Specifi	Accurac	Youden	PPV	NPV	
	Auc	value	point	ity	city	y	's Index	11 4	1 <b>11 V</b>	
90 d mRS (Good vs. Poor)										
	0.770			64.5%	76.0%	69.6%	40.5%	76.9%	63.3%	
HIR	0.648-	0.001*	≤0.3	45.4–	54.9–	55.9–	16.8–	56.4-	42.0.00.404	
	0.893			80.8%	90.6%	81.2%	64.3%	91.0%	43.9–80.1%	
				67.7%	68.0%	67.9%	35.7%	72.4%	63.0%	
			≤0.4	48.6–	46.5–	54.0-	11.1–	52.8-	12.4.00.60/	
				83.3%	85.1%	79.7%	60.3%	87.3%	42.4–80.6%	
	0.730			71.0%	76.0%	73.2%	47.0%	78.6%	67.9%	
CBV Index	0.595-	0.003*	≥0.7	52.0-	54.9–	59.7–	23.8-	59.0-	47 ( 04 10/	
	0.865			85.8%	90.6%	84.2%	70.1%	91.7%	47.6–84.1%	
				35.5%	92.0%	60.7%	27.5%	84.6%	53.5%	
			≥0.8	19.2-	74.0–	46.8–	7.6%-	54.6-	27 7 60 004	
				54.6%	99.0%	73.5%	47.4%	98.1%	37.7–68.8%	
p-value										
(DeLong test										
between CBV	0.558									
index and HIR)										
			9(	 0 d mRS (E	Excellent v	 s. Poor)				
	0.741			69.6%	69.7%	69.6%	39.3%	61.5%	76.7%	
HIR	0.601-	<0.001	≤0.3	47.1–	51.3-	55.9–	14.8–	40.6–		
	0.881	*		86.8%	84.4%	81.2%	63.7%	79.8%	57.7–90.1%	
				69.6%	60.6%	64.3%	30.2%	55.2%	74.1%	
			≤0.4	47.1–	42.1–	50.4–	5.0%–	35.7–	53.7–88.9%	

				86.8%	77.1%	76.6%	55.3%	73.6%	
	0.733	<0.001		73.9%	66.7%	69.6%	40.6%	60.7%	78.6%
CBV Index	0.596–	*	≥0.7	51.6-	48.2-	55.9–	16.5-	40.6–	59.0–91.7%
	0.871			89.8%	82.0%	81.2%	64.7%	78.5%	39.0-91.770
				39.1%	87.9%	67.9%	27.0%	69.2%	67.4%
			≥0.8	19.7–	71.8–	54.0-	4.2%—	38.6–	51.5–80.9%
				61.5%	96.6%	79.7%	49.9%	90.9%	31.5-00.770
p-value									
(DeLong test	0.906								
between CBV	0.700								
index and HIR)									

AUC: Area under curve. \*Significant (<0.050). PPV: Positive Predictive Value. NPV: Negative Predictive Value.

# **Figures**




Figure (1): Receiver Operating Characteristics (ROC) curve for HIR and CBV in predicting good 90mRS

Table (1): Demographic, admission findings, and vessel breakdown according to optimal CBV index threshold

		All cases CBV Index based CS			
Variables		Good CS ≥0.7	Poor CS < 0.7	p-value	
	(1 otal=60)	(Total=30)	(Total=30)	1	
Age (years)		73.3±15.2	69.0±12.4	^0.230	
Sex Female		20 (66.7%)	15 (50.0%)	#0 100	
Male	25 (41.7%)	10 (33.3%)	15 (50.0%)	#0.190	
Black	34 (56.7%)	16 (53.3%)	18 (60.0%)		
White	24 (40.0%)	13 (43.3%)	11 (36.7%)	§0.893	
Asian	2 (3.3%)	1 (3.3%)	1 (3.3%)	1	
	28.2±5.6	28.3±5.8	28.1±5.6	^0.932	
	31 (51.7%)	15 (50.0%)	16 (53.3%)	#0.796	
	18 (30.0%)	7 (23.3%)	11 (36.7%)	#0.260	
n	51 (85.0%)	25 (83.3%)	26 (86.7%)	§0.999	
	38 (63.3%)	19 (63.3%)	19 (63.3%)	#0.999	
	20 (33.3%)	10 (33.3%)		#0.999	
/ TIA	35 (58.3%)	16 (53.3%)	19 (63.3%)	#0.432	
	15 (25.0%)	8 (26.7%)	7 (23.3%)	#0.766	
Glucose (mg/dL)		155.2±93.6	131.2±41.0	^0.204	
BUN (mg/dL)		23.3±11.7	18.1±10.3	^0.071	
Creatinine (mg/dL)		1.4±1.2	1.1±0.4	^0.287	
(gm/dL)	12.6±1.9	12.4±2.0	12.9±1.7	^0.219	
nL)	9.7±8.8	10.9±12.1	8.4±2.8	^0.258	
0 <sup>3</sup> /mL)	242.6±85.3	254.8±82.4	230.4±87.7	^0.271	
THSS	10.5 (4.5–17.5)	9.0 (4.0–15.0)	13.5 (5.0–19.0)	¤0.208	
	9.0 (8.0–10.0)	9.0 (8.0–10.0)	9.0 (8.0-10.0)	¤0.845	
Large artery atherosclerosis	10 (16.9%)	7 (23.3%)	3 (10.3%)		
Cardioembolism	26 (44.1%)	15 (50.0%)	11 (37.9%)	#0.115	
Stroke of undetermined etiology	23 (39.0%)	8 (26.7%)	15 (51.7%)	#0.113	
	51 (85.0%)	28 (93.3%)	23 (76.7%)		
	`			§0.115	
				- go.113	
		\ /			
				#0.301	
				1	
			` /	§0.770	
				7 30	
	Female Male Black White Asian  The second of	Total=60	Triables   Total=60   Good CS 20.7   (Total=30)		

BMI: Body mass index. Data presented as n (%), Mean±SD and Median (1st-3rd IQ). SBP: Systolic blood pressure. DBP: Diastolic blood pressure. HR: Heart rate. RR: Respiratory rate. §Fishers Exact test. #Chi square test. ^Independent t-test. ¤Mann-Whitney test. \*Significant (<0.050)

Table (2): Collateral parameters, interventional parameters, and clinical outcomes based on optimal CBV index threshold

	All cases	CBV Index	based CS	
Variables and Outcomes	(Total=60)	Good CS ≥0.7	Poor CS < 0.7	p-value
	(10tal-00)	(Total=30)	(Total=30)	
IV tpa	19 (31.7%)	11 (36.7%)	8 (26.7%)	#0.405
Anesthesia	4 (6.7%)	2 (6.7%)	2 (6.7%)	§0.999

Number of Pa		1.0 (1.0–2.0)	1.0 (1.0-1.0)	1.0 (1.0-2.0)	¤0.068	
Last known v	vell to Door	243.0 (63.0-	239.5 (75.0-	244.5 (61.0-	¤0.882	
(min.)			596.0)	568.0)	₩0.882	
Symptom ons	Symptom onset to Door		60.0 (47.0-	55.0 (48.0-	¤0.378	
(min.)		144.0)	146.0)	65.0)	20.578	
Door to CT (	: \	26.5 (15.5-	26.0 (15.0–37.0)	27.0 (16.0-	¤0.750	
Door to CT (1	nin.)	37.0)	20.0 (13.0–37.0)	42.0)	20.730	
Last known w	vell to CT	272.0 (86.5–	269.5 (85.0-	281.5 (88.0-	¤0.882	
(minutes)		610.0)	619.0)	580.0)	≅0.882	
Door to needl	a tima (min )	67.0 (55.0–	67.0 (55.0–87.0)	72.0 (55.0-	¤0.680	
Door to need	e ume (mm.)	115.0)	67.0 (33.0–87.0)	125.5)	≌0.080	
Door to groin	puncture	148.5 (122.5–	143.5 (111.0-	152.5 (133.0-	¤0.169	
(min.)		181.5)	175.0)	195.0)	≅0.109	
Groin Punctu		25.0 (18.0–	24.0 (15.0–29.0)	26.0 (20.0–	¤0.231	
Pass (minutes		32.0)	` '	33.0)	~0.231	
Door to recan	alization,	418.5 (243.0–	397.0 (258.0–	479.0 (210.0-	¤0.824	
(min.)		732.0)	764.0)	715.0)	≈0.624	
	First Pass to		5.0 (3.5–6.0)	8.0 (4.0–21.0)	¤0.078	
	recanalization, (min.)		2.0 (3.3 0.0)	` ,		
	<b>Groin Puncture to</b>		30.0 (20.0–39.0)	40.0 (26.0–	¤0.056	
recanalization		48.0)	2010 (2010 2510)	55.0)	0.020	
Hemorrhagic		15 (25.0%)	5 (16.7%)	10 (33.3%)	#0.136	
Transformati		` ′	` ′	` ′		
mTICI	2b	17 (26.6%)	9 (26.7%)	8 (26.7%)		
score	3	43 (71.7%)	22 (73.3%)	21 (70.0%)	0.999	
		` ´				
	0	4 (8.7%)	0 (0.0%)	4 (100%)		
	1	6 (13.0%)	0 (0.0%)	6 (100%)	§ <b>0.004</b> *	
DSA grades	2	6 (13.0%)	4 (66.7%)	2 (33.3%)	3	
	3	20 (43.5%) 10 (21.7%)	14 (70.0%)	6 (30.0%)		
	4		5 (50.0%)	5 (50.0%)		
DSA based Good		30 (65.2%)	19 (63.3%)	11 (36.7%)	#0.013*	
CS Poor		16 (34.8%) 0.4 (0.1–0.5)	4 (25.0%)	12 (75.0%)		
	HIR		0.3 (0.0–0.5)	0.5 (0.3–0.6)	¤0.001*	
NIHSS discha	arge	2.0 (1.0–6.0)	2.0 (1.0–5.0)	6.0 (2.0–12.0)	¤0.001*	
NIHSS shift		-6.0 (-13.0–0.0)	-10.5 (-16.0	-3.0 (-6.0–3.0)	¤<0.001*	
		` ′	4.0)	` ′		
Discharge mI	RS	3.0 (2.0–4.0)	2.0 (2.0–3.0)	4.0 (3.0–5.0)	¤<0.001*	
90-da7 mRS		2.0 (1.0-4.0)	1.0 (0.0-2.0)	4.5 (3.0–6.0)	¤<0.001*	

Data presented as n (%), Mean±SD and Median (1st-3rd IQ). §Fishers Exact test. #Chi square test. ^Independent t-test. ¤Mann-Whitney test. \*Significant (<0.050)

Table (3): Multivariate logistic regression for predicting good clinical outcomes

Factors	β	SE	p-value	OR (95% CI)				
Good 90mRS								
Stroke	roke -1.10 0.49 0.024* 0.13 (0.33-0.86)							
CBV index ≥0.7	1.94	0.57	0.001*	2.27 (6.94–21.23)				

β: Regression coefficient, SE: Standard error, OR: Odds ratio, CI: Confidence interval, \*significant

Table (4): CBV index and HIR correlations with other parameters

Factors	CBV	index	HIR			
	r	p-value	r	p-value		
90mRS	-0.693	<0.001*	0.687	<0.001*		
DSA	0.236	0.114	-0.134	0.373		
HIR	-0.494	<0.001*				

Spearman correlation. \*Significant

Table (5): Diagnostic performance of CBV index and HIR in predicting good and excellent clinical outcomes

	AUC	p- value	Cut point	Sensitiv ity	Specifi city	Accur acy	Youden 's Index	PPV	NPV
90 d mRS (Good vs. Poor)									
	0.770			64.5%	76.0%	69.6%	40.5%	76.9%	63.3%
HIR	0.648-	0.001*	≤0.3	45.4-	54.9-	55.9-	16.8-	56.4-	43.9-
	0.893			80.8%	90.6%	81.2%	64.3%	91.0%	80.1%
				67.7%	68.0%	67.9%	35.7%	72.4%	63.0%
			≤0.4	48.6–	46.5-	54.0-	11.1-	52.8-	42.4-
				83.3%	85.1%	79.7%	60.3%	87.3%	80.6%
	0.730			71.0%	76.0%	73.2%	47.0%	78.6%	67.9%
CBV Index	0.595-	0.003*	≥0.7	52.0-	54.9-	59.7-	23.8-	59.0-	47.6–
	0.865			85.8%	90.6%	84.2%	70.1%	91.7%	84.1%
				35.5%	92.0%	60.7%	27.5%	84.6%	53.5%
			≥0.8	19.2-	74.0-	46.8-	7.6%-	54.6-	37.7-
				54.6%	99.0%	73.5%	47.4%	98.1%	68.8%
p-value (DeLong test between CBV index and HIR)	0.558								
	1	ı	90 d m	RS (Excell			ı	1	
	0.741	<0.001		69.6%	69.7%	69.6%	39.3%	61.5%	76.7%
HIR	0.601-	*	≤0.3	47.1–	51.3-	55.9–	14.8–	40.6–	57.7-
	0.881			86.8%	84.4%	81.2%	63.7%	79.8%	90.1%
				69.6%	60.6%	64.3%	30.2%	55.2%	74.1%
			≤0.4	47.1–	42.1-	50.4-	5.0%-	35.7–	53.7–
				86.8%	77.1%	76.6%	55.3%	73.6%	88.9%
	0.733	<0.001		73.9%	66.7%	69.6%	40.6%	60.7%	78.6%
CBV Index	0.596-	*	≥0.7	51.6-	48.2-	55.9–	16.5-	40.6–	59.0-
	0.871			89.8%	82.0%	81.2%	64.7%	78.5%	91.7%
				39.1%	87.9%	67.9%	27.0%	69.2%	67.4%
			≥0.8	19.7–	71.8–	54.0-	4.2%-	38.6–	51.5-
				61.5%	96.6%	79.7%	49.9%	90.9%	80.9%
p-value (DeLong test	0.906								

Page 3 of 4

between CBV index					
and HIR)					

AUC: Area under curve. \*Significant (<0.050). PPV: Positive Predictive Value. NPV: Negative Predictive Value.




Figure (1): Receiver Operating Characteristics (ROC) curve for HIR and CBV in predicting good 90mRS




Figure (1): Receiver Operating Characteristics (ROC) curve for HIR and CBV in predicting good 90mRS